BCAB
Bioatla Inc
NASDAQ: BCAB · HEALTHCARE · BIOTECHNOLOGY
$4.21
+4.21% today
Updated 2026-04-30
Market cap
$8.07M
P/E ratio
—
P/S ratio
4.04x
EPS (TTM)
$-50.50
Dividend yield
—
52W range
$4 – $72
Volume
1.0M
Bioatla Inc (BCAB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.63M | $5.20M | $429000.00 | $250000.00 | $0.00 | $0.00 | $11.00M | $2.00M |
| Revenue growth (YoY) | — | -51.1% | -91.8% | -41.7% | -100.0% | — | — | -81.8% |
| Cost of revenue | $26.30M | $25.92M | $19.93M | $1.33M | $1.20M | $1.22M | $925000.00 | — |
| Gross profit | $-15.68M | $-20.72M | $-19.50M | $250000.00 | $-1.20M | $-1.22M | $10.07M | $2.00M |
| Gross margin | -147.5% | -398.4% | -4546.4% | 100.0% | — | — | 91.6% | 100.0% |
| R&D | $26.30M | $25.92M | $19.93M | $58.27M | $79.35M | $103.73M | $63.09M | $43.57M |
| SG&A | $12.56M | $7.55M | $10.60M | $38.42M | $28.79M | $25.96M | $21.85M | $17.73M |
| Operating income | $-28.23M | $-28.27M | $-30.10M | $-96.44M | $-108.14M | $-129.69M | $-73.94M | $-59.30M |
| Operating margin | -265.7% | -543.6% | -7016.1% | -38576.0% | — | — | -672.2% | -2965.3% |
| EBITDA | $-27.24M | $-27.41M | $-33.46M | $-94.07M | $-105.28M | $-122.24M | $-73.02M | $-58.93M |
| EBITDA margin | -256.3% | -527.1% | -7798.6% | -37627.6% | — | — | -663.8% | -2946.6% |
| EBIT | $-28.03M | $-28.27M | $-34.46M | $-95.40M | $-106.48M | $-123.46M | $-73.94M | $-59.30M |
| Interest expense | $949000.00 | $1.63M | $1.39M | $3000.00 | $1.66M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-28.98M | $-29.79M | $-35.85M | $-95.40M | $-105.28M | $-123.46M | $-69.78M | $-59.61M |
| Net income growth (YoY) | — | -2.8% | -20.3% | -166.1% | -10.4% | -17.3% | +43.5% | +14.6% |
| Profit margin | -272.7% | -573.0% | -8357.3% | -38160.8% | — | — | -634.3% | -2980.3% |